Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Vector Pharma Signs Distribution Agreement for Skytrofa and Yorvipath
Details : Vector will distribute Skytrofa (lonapegsomatropin-tcgd) for pediatric growth hormone deficiency and Yorvipath for adult hypoparathyroidism in the GCC countries, using its sales expertise.
Product Name : Skytrofa
Product Type : Hormone
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : R-Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East
Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.
Product Name : Ixempra
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 22, 2021
Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : R-Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement